SEARCH

SEARCH BY CITATION

References

  • 1
    Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 51548.
  • 2
    Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 22839.
  • 3
    Peggs KS, Quezada SA, Korman AJ, Allison J P. Principles and use of CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 20613.
  • 4
    Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, Garbe C, Gomez-Navarro J, Pavlov D, Marshall M. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA9011).
  • 5
    Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M,   A, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O’Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology 2010; 11: 15564.
  • 6
    O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 17127.
  • 7
    Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O’Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budeso-nide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 55918.
  • 8
    Smylie M, Francis S, Neyns B, Maio M, Minor D, Verschraegen C, Chin K, Ibrahim R, Hoos A, Schadendorf D. Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. J Clin Oncol 2009; 27: 15s, (suppl; abstr 9041).
  • 9
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, Van Den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette G P, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with meta-static melanoma. N Engl J Med 2010; 363(8): 71123.
  • 10
    Lawrence D P, Hamid O, McDermott D F, et al : Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; June 48, 2010; Chicago , IL . J Clin Oncol 2010; 28: 15s (suppl; abstr 8523).
  • 11
    Tsianakas A, Schiller M, Luger TA, Sunderkötter C. The option of compassionate use in metastatic melanoma – way out of a therapeutic dilemma? J Dtsch Dermatol Ges 2009; 7: 6719.
  • 12
    Lebbe C, O’Day S, Chiarion Sileni V, Gajewski T, Pehamberger H, Bondarenko I, Queirolo P, Lundgren S, Roman L, Verschraegen C, Ibrahim R, Chin K, Hoos A, Maio M. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with meta-stastic melanoma. (oral abstract O-015, Perspectives in Melanoma XII 2008).
  • 13
    Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison J P, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 47127.
  • 14
    Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008; 26: (May 20 suppl; abstr 9063).
  • 15
    Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 253840.
  • 16
    Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Mel Research 2009; 19: 3334.
  • 17
    Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004; 27: 4789.
  • 18
    Attia P, Phan GQ, Maker AV, Robinson MR, Quezada MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo N P, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Clin Oncol 2005; 23: 604353.
  • 19
    Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Canc Res 2007; 13: 66818.
  • 20
    Lutzky J, Wolchok J, Hamid O, Lebbe C, Pehamberger H, Linette G, de Pril V, Ibrahim R, Hoos A, O’Day S. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol 2009; 27: 15s, (suppl; abstr 9034).
  • 21
    Pavlov D, Marshall MA; Pfizer Oncology, New London, CT; Pfizer Oncology Global Research and Development, New London, CT. Association of adverse events and tumor response in melanoma patients treated with tremelimumab. J Clin Oncol 2010; 28, (suppl; abstr e13104).